Previcox

None.

Revised: July 2024
AN: 00396/2023 Page 2 of 7

Special precautions for use in animals
The recommended dose, see section 4.9, should not be exceeded.
Use in very young animals, or animals with suspected or confirmed impairment of
renal, cardiac or hepatic function may involve additional risk. If such use cannot be
avoided, those dogs require careful veterinary monitoring.
Avoid use in dehydrated, hypovolaemic or hypotensive animals, as there is a
potential risk of increased renal toxicity. Concurrent administration of potentially
nephrotoxic drugs should be avoided.
Use this product under strict veterinary monitoring where there is a risk of
gastrointestinal bleeding, or if the animal previously displayed intolerance to
NSAIDs. Renal and/or hepatic disorders have been reported in very rare cases in
dogs administered the recommended treatment dose. It is possible that a proportion
of such cases had sub-clinical renal or hepatic disease prior to the commencement
of therapy. Therefore, appropriate laboratory testing to establish baseline renal or
hepatic biochemistry parameters is recommended prior to and periodically during
administration.
The treatment should be discontinued if any of these signs are observed: repeated
diarrhoea, vomiting, faecal occult blood, sudden weight loss, anorexia, lethargy,
degradation of renal or hepatic biochemistry parameters.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Wash hands after use of the product.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Divided tablets should be returned to the original package.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.